Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.
Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar TC, Nguyen AT, Desta Z, Storniolo AM, Flockhart DA, Hayes DF, Stearns V; COBRA investigators.
Rae JM, et al. Among authors: oesterreich s.
Pharmacogenomics J. 2009 Aug;9(4):258-64. doi: 10.1038/tpj.2009.14. Epub 2009 May 5.
Pharmacogenomics J. 2009.
PMID: 19421167
Free PMC article.
Clinical Trial.